Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens

Table 3 Baseline and efficacy profile for nanoliposomal irinotecan-based therapy from NAPOLI-1 [12]

Characteristics^a	Results
N	117
Karnofsky performance 100–80	91%
Lines of prior therapy: 0/1/2+ (%)	13/53/34
Prior therapy: Gemcitabine mono/combination/5-FU-based (%)	45/55/43
Median OS (95% CI)	6.1 months (4.8–8.9)

Abbreviations: 5-FU 5-fluorouracil, CI confidence interval, ECOG Eastern Cooperative Oncology Group, N patients in study, OS overall survival
^aFor patients with ECOG 0–1, the poster median of the median OS for 5-FU and oxaliplatin-based therapy and FOLFOX in second-line are 6.2 months and 6.3 months, respectively

ISSN: 1471-2407